MedTrace Logo

Physiology of GIP(1-30)NH2 in Humans

NCT04792762 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-03-11

No results posted yet for this study

Summary

Glucose-dependent insulinotropic polypeptide (GIP) is a gut-derived incretin hormone that affects glucose, lipid and bone metabolism. Secretion of GIP into the blood stream from enteroendocrine cells is stimulated bu nutrients in the gut lumen and results in potentiation of glucose stimulated insulin secretion from the pancreas. The objective of this study is to investigate the physiology of GIP(1-30)NH2 in humans with insulin secretion as the primary endpoint. Furthermore the effects on on plasma/serum levels of glucagon, C-peptide, glucose, bone markers (CTX and P1NP) will be measured.

Conditions

  • Glucose Metabolism Disorders

Interventions

OTHER

GIP(1-30)NH2

Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp

OTHER

GIP(1-42)

Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp

OTHER

Saline

Intravenous administration of saline during a stepwise glucose clamp

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2018-08-23
Completion
2019-06-09

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04792762 on ClinicalTrials.gov